On September 2, 2025, Enlaza Therapeutics, the first covalent biologics platform company, announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the transaction.

Under the collaboration, Enlaza will receive $45 million inclusive of an upfront payment and equity investment, and is further eligible to receive more than $2 billion in future milestone payments, including research, development, regulatory, and commercial milestones, plus tiered royalties on net sales. Enlaza will lead all research activities through development candidate nomination, and Vertex will subsequently lead all future research, development, manufacturing, and commercialization of successful product candidates. Vertex will fund all research and development costs related to the four-year collaboration.

The Wilson Sonsini team that advised Enlaza on IP matters included Deborah Smith, Michael Hostetler, Sean Reed, and Victoria Cheng.

For more information, please see Enlaza’s press release. Additional coverage can be found on BioSpace, Fierce Biotech, and PharmExec.com.